German Biotechnology Company, BioNTech, plans to start distributing a new Coronavirus vaccine that has been developed to neutralise two Omicron variants early next month.
“We will be able to deliver very soon, hopefully at the beginning of September,” BioNTech chief executive, Ugur Sahin said.
The European Medicines Agency (EMA) recently announced that it would take a decision on applications from BioNTech/Pfizer and Moderna regarding their vaccines adapted for the BA.1 variant of the virus.
However, this variant is of declining importance in Europe.
The new vaccine was however still expected to be more effective in neutralising the variants currently in circulation.
EMA is currently testing a vaccine adapted by BioNTech and its U.S. partner Pfizer for the BA.4 and BA.5 variants currently dominant in Europe.
BioNTech was currently submitting the last documents to the EMA, Sahin said.
“Then things can precede quickly here as well,” he said.